{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=19&q=HNSCC",
    "query": {
      "q": "HNSCC",
      "condition": "Head and Neck Cancer",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 1257,
    "total_pages": 126,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=20&q=HNSCC&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=18&q=HNSCC&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T11:37:55.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04272333",
      "title": "Intratumoral Microdosing of Motolimod in HNSCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "HNSCC"
      ],
      "interventions": [
        {
          "name": "Motolimod",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Motolimod + Nivolumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-10-15",
      "completion_date": "2022-03-25",
      "has_results": false,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Chicago, Illinois • Winston-Salem, North Carolina + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04272333"
    },
    {
      "nct_id": "NCT00041626",
      "title": "Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell"
      ],
      "interventions": [
        {
          "name": "INGN 201",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Introgen Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-09-11",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041626"
    },
    {
      "nct_id": "NCT06159621",
      "title": "CD40 Agonist and PD-1 Inhibitor in HNSCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PD-1inhibitor - LVGN 3616",
          "type": "DRUG"
        },
        {
          "name": "CD 40 Agonist - LVGN 7409",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2024-07-02",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06159621"
    },
    {
      "nct_id": "NCT05432193",
      "title": "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Melanoma (Skin)",
        "Soft Tissue Sarcoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "[Ga-68]-PNT6555",
          "type": "DRUG"
        },
        {
          "name": "[Lu-177]-PNT6555",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-07-13",
      "completion_date": "2024-10-02",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432193"
    },
    {
      "nct_id": "NCT00248560",
      "title": "Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 36,
      "start_date": "2005-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248560"
    },
    {
      "nct_id": "NCT03129061",
      "title": "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CellSight Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-05-01",
      "completion_date": "2022-12-01",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03129061"
    },
    {
      "nct_id": "NCT00662662",
      "title": "Sexual Behavior in Head and Neck Cancer Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oropharyngeal Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2008-04",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2020-12-30",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662662"
    },
    {
      "nct_id": "NCT03254927",
      "title": "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "CDX-3379 and cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-03-27",
      "completion_date": "2020-12-16",
      "has_results": true,
      "last_update_posted_date": "2023-04-03",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03254927"
    },
    {
      "nct_id": "NCT01949740",
      "title": "Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage II Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2013-06",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-02",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01949740"
    },
    {
      "nct_id": "NCT05451303",
      "title": "Detection of Oral and Throat Cancers Using OralViome Cancer Testing System",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oral Squamous Cell Carcinoma",
        "Oropharynx Squamous Cell Carcinoma",
        "Premalignant Lesion"
      ],
      "interventions": [
        {
          "name": "OralViome Cancer Testing System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Viome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 475,
      "start_date": "2022-05-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-10-21T11:37:55.135Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05451303"
    }
  ]
}